The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories
![Denmark Denmark flag](https://www.greenhill.com/sites/default/files/denmark_flag%5B1%5D.gif)
Global collaboration agreement with Genmab A/S
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
![](https://www.greenhill.com/sites/default/files/new_project_0.png)
Nutrition & Biosciences Division of DuPont de Nemours, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising IFF, a global leader in flavors and fragrances, on its merger with DuPont’s Nutrition & Biosciences Division, creating a clear global leader in the specialty ingredients sector
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Unfors Raysafe AB
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Biotage (Biosystems division)
![Netherlands Netherlands flag](https://www.greenhill.com/sites/default/files/niederland.gif)
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research